These are the stocks posting the largest moves before the bell.Market Insiderread more
U.S. stock futures pointed to a higher open on Monday as Treasury yields rebounded to quell fears of a possible recession.US Marketsread more
The Business Roundtable, a group of CEOs of nearly 200 major U.S. corporations, gave a new definition of the "purpose of a corporation."Marketsread more
Trump said he doesn't see a recession after the bond market spooked investors and the Dow suffered its worst day of the year last week.Marketsread more
Bianco Research's James Bianco suggests Wall Street is desperately looking for a signal that a 50 basis point cut is coming next month.Trading Nationread more
Amid the headlines of stores closures and retail bankruptcies, it can be tough to accept that the U.S. consumer is doing just fine.Retailread more
U.S. Commerce Secretary Wilbur Ross said the U.S. will extend a reprieve given to Huawei that permits the Chinese firm to buy supplies from U.S. companies.Politicsread more
Here are the biggest calls on Wall Street on MondayInvestingread more
Goldman notes that high-dividend payers are trading at their largest valuation discount in nearly 40 years.Marketsread more
Dow to jump; Trump defends economy; Huawei hopes for US reprieve; Trump and Apple's Tim Cook meet; president ties Hong Kong protests to China trade disputeMarketsread more
We tested the best way to cut the airport commute time for New Yorkers. The most expensive of the four options we reviewed, Uber Copter, was only 14 minutes faster than mass...Transportationread more
How high can prices go when it comes to saving lives?
U.S. lawmakers are scrutinizing the price of Sovaldi, a new hepatitis C drug produced by Gilead Sciences, and have asked the biotech company to explain why it cost $1,000 a pill.
The $84,000 price tag for a three-month treatment has health insurers and state Medicaid programs nervous as it is difficult to draw a line between what the company charges and what it costs to produce it.
"It makes an easy target, certainly for politicians or for folks, but I think the more important constituency here are our payers," Christopher Raymond, an R.W. Baird biotech analyst, told CNBC's "Squawk Box " on Monday.
(Read more: )
Raymond said biotech companies do not encounter such problems in other parts of the world because health-care systems are so different. Europe, for example, has a single-payer system in which governments cover health-care costs.
"Alexion [Pharmaceuticals], which has their own high-price drug, are in the midst of a new product cycle in Europe, ... where they are winning that battle every day, " he said.
(Read more: )
But the United States lacks such a system, and "until we get that, I think this is just headlines," Raymond said.
Gilead has said it has been working with a number of stakeholders, including federal and state officials, and looks forward to meeting with members of Congress to address concerns about Sovaldi, according to Reuters.
—By CNBC's Mathilde Hamel. Follow her on Twitter